Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer by �젙�씗泥� et al.
Kim et al. BMC Cancer 2013, 13:394
http://www.biomedcentral.com/1471-2407/13/394RESEARCH ARTICLE Open AccessPrediction of metachronous multiple primary
cancers following the curative resection of gastric
cancer
Chan Kim1,2, Hong Jae Chon1,2, Beodeul Kang1,2, Kiyeol Kim4, Hei-Cheul Jeung1,2,3, Hyun Cheol Chung1,2,3,5,
Sung Hoon Noh1,5,6 and Sun Young Rha1,2,3,5*Abstract
Background: Due to improved survival rate, gastric cancer (GC) patients have an increased risk of developing
multiple primary cancer (MPC). The purpose of this study is to evaluate the clinicopathological features of MPC
and to generate useful tools for the prediction of metachronous MPC following gastrectomy.
Methods: 3066 patients who underwent curative resection of GC were reviewed retrospectively, based on the
clinical information and the medical record.
Results: The 5-year incidence of MPC was 2.5%. Of these, 54.3% had a metachronous MPC, while 45.7% had a
synchronous MPC. The most prevalent site of metachronous MPC was the colorectum (26.3%), followed by lung
(23.7%) and liver (18.4%). Multivariate logistic regression analysis revealed that old age at the time of GC diagnosis
(≥60 years), early stage of GC (stage I and II), and multiplicity of GC at the time of gastrectomy were independent
predictive factors for metachronous MPC. GC patients with either metachronous or synchronous MPC showed
poorer survival than patients without MPC. In addition, patients with a metachronous MPC showed late survival
disadvantage, while patients with a synchronous MPC showed early survival disadvantage. Furthermore, we were
able to develop and internally validate a nomogram to predict the metachronous MPC after curative gastrectomy
(C-index = 0.72).
Conclusion: Patients at high risk of developing metachronous MPC after curative resection of GC were identified.
Individual risk of developing metachronous MPC could be predicted by a novel nomogram. Further external
validation with independent patient cohorts is required to improve the accuracy of prediction.
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Gastric cancer (GC) is the fourth most common cancer
and the second leading cause of cancer-related death
worldwide, and is especially prevalent in the Asia-Pacific
region [1]. In recent years, the emphasis on regular can-
cer screening programs and advances in diagnostic tech-
niques has greatly improved the detection rate of early
gastric cancer (EGC) [2]. In Korea, a population-based
mass-screening program for GC was initiated by the* Correspondence: rha7655@yuhs.ac
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reproduction in any medium, provided the orMinistry of Health and Welfare in 2002. This screening
program recommends a biennial upper gastrointestinal
series or endoscopy for people over 40 years old [3]. Al-
though this screening program does not completely
cover the target population, it already has led to an in-
crease in the detection rate of EGCs from 33% in 1999
to 60% in 2012, and has subsequently contributed to an
improved clinical outcome for GC [4]. In addition, ad-
vances in surgical techniques and multimodal treatments
have also improved survival [2,5,6]. Because of this pro-
longation in survival, GC patients live longer, but have
a greater possibility of developing multiple primary
cancer (MPC).. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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GC, early screening and proper management of MPC in
GC survivors is of particular importance. To date, few
studies have investigated the incidence and clinical pat-
tern of MPC in GC patients and most of these studies
have been limited to some subsets of patients. Moreover,
little is known about the risk factors predictive of MPC
following curative gastrectomy [7-11].
The aim of the present study was to determine the
clinicopathological features and outcomes of MPC, with
the goal of generating useful predictive tools for MPC in
GC survivors.
Methods
Between 2000 and 2004, 3066 patients underwent resec-
tion of GC with the curative aim at the Yonsei Cancer
Center, Severance Hospital (Yonsei University Health
System, Korea). All of these patients were analyzed
retrospectively using the medical record from our insti-
tute. The study was approved by the institutional review
board of Severance Hospital. The criteria of Warren and
Gates [12] were used to define MPC: 1) The tumor must
have definite malignancy features; 2) The tumor has to
be separate and distinct from the index tumor, which
was gastric adenocarcinoma in the present study; 3) The
possibility of the tumor being a metastasis of the index
tumor should be ruled out. Patients with multiple pri-
mary GC in the remnant stomach after gastrectomy
were not included.
All patients underwent a complete blood count, rou-
tine chemistry, upper endoscopy, chest radiography, and
abdominal computed tomography at the time of GC
diagnosis. Clinicopathological characteristics, including
sex, age of GC diagnosis, stage, multiplicity, location, cell
type of GC, type of gastrectomy, maximal length of GC
mass, initial CEA level, CA 19–9 level, site of MPC, time
interval between GC and MPC, history of smoking and
alcohol, and clinical outcome were assessed. Multiple
gastric cancer included multiple synchronous gastric
cancers, multiple cancers in the remnant stomach, and
the GC patients with the history of prior endoscopic
mucosal resection (EMR) or endoscopic submucosal dis-
section (ESD).
Pathological diagnosis and classification of the cancer
was made according to the criteria of the American Joint
Committee on Cancer 2002 staging system. For the diag-
nosis of hepatocellular carcinoma, the AASLD (American
Association for the Study of Liver Disease) criteria were
used, which consist of elevated serum α-fetoprotein level
> 200 ng/ml or typical pattern of enhancement on dy-
namic imaging of hepatic mass . 2 cm in a cirrhotic liver
[13]. After being discharged from the hospital, all patients
took part in a regular follow-up program. Patients were
followed-up on every three months within the first twoyears, every four months during the third year, every six
months during the fourth and fifth year, and once every
year thereafter. Synchronous MPC was defined as MPC
diagnosed within 6 months of GC diagnosis, while
metachronous MPC was defined as MPC diagnosed more
than 6 months after the GC diagnosis. Overall survival
was defined as the time from the curative gastrectomy to
death or to last follow-up. We reviewed the causes of
death based on the medical records of our institute and
the survival database of the National Statistical Office.
The Statistical Package for Social Sciences version 17.0
for Windows (SPSS, Inc., Chicago, IL) was used for stat-
istical analysis. Chi-square tests and independent sample
t-test were used for the analysis of variables. The sur-
vival curve was evaluated using the Kaplan-Meier
method, and statistical differences were analyzed using
the log-rank test. The accepted level of significance was
p < 0.05.
The nomogram was established by using selected risk
factors for predicting an individual patient’s probability
of developing metachronous MPC within 5-years after
gastrectomy. For the development of MPC predicting
nomogram, 32 patients with synchronous MPC were
excluded, and remaining 3034 patients were analyzed
following Kattan’s method [14]. The nomogram was vali-
dated using concordance index (c-index) and a calibra-
tion plot [15]. Calibration was performed by comparing
the accuracy between the actual incidence of MPC and
the nomogram-predicted incidence of MPC. The statis-
tical analysis for the nomogram was performed using R
program (http://www.r-project.org/).
Results
Patient characteristics and detection of MPC
Table 1 shows the baseline characteristics of the cohort.
The mean age at diagnosis of GC was 57.3 years old and
the male-to-female ratio was 2.06 to 1. The median follow-
up duration was 60.3 months. 587 patients (18.9%) experi-
enced the recurrence after the curative resection of GC.
Among recurred patients, most common location of recur-
rence was the peritoneum (162 cases), followed by lymph
node (100 cases), liver (88 cases), anastomosis site (39
cases), bone (22 cases), and remnant stomach (20 cases).
Among 3,066 patients with GC, 70 (2.3%) were found to
have a MPC. Of these, 38 (54.3%) had a metachronous
MPC, while 32 (45.7%) had a synchronous MPC. When
considering the censored cases, the 5-year cumulative in-
cidence of metachronous MPC after the diagnosis of GC
was 1.4%. The majority of metachronous MPC occurred
within three years from the diagnosis of GC. The mean
interval between the diagnosis of GC and metachronous
MPC was 25.5 months. However, some metachronous
MPCs were found even after three years, suggesting that
metachronous MPC can occur at any time after
Table 1 Baseline characteristics of GC
Frequency (%)
(n = 3066)
Sex
Male 2065 (67.4%)
Female 1001 (32.6%)
Age at diagnosis 57.3 ± 11.8
Stage
I 1640 (53.5%)
II 448 (14.6%)
III 736 (24.0%)
IV 242 (7.9%)
Multiplicity
Single 2860 (93.3%)
≥2 206 (6.7%)
Location
Upper 1516 (50.4%)
Mid 1023 (34.0%)
Lower 351 (11.7%)
Diffuse 116 (3.9%)
Cell type
Tubular 2390 (78.0%)
Adeno WD 406 (13.2%)
Adeno MD 859 (28.0%)
Adeno PD 1125 (36.7%)
Signet ring cell 514 (16.8%)
Mucinous 73 (2.4%)
Others 89 (2.9%)
Table 2 Clinicopathological characteristics of GC
according to presence of metachronous MPC
No MPC Meta MPC P value
(n = 2996) (n = 38)
Sex
Male 2010 (67.1%) 32 (84.2%) 0.025
Female 986 (32.9%) 6 (15.8%)
Age 57.2 ± 11.8 63.6 ± 7.7 <0.001
Stage
I 1598 (53.3%) 26 (68.4%) 0.011
II 430 (14.4%) 9 (23.7%)
III 726 (24.2%) 3 (7.9%)
IV 242 (8.1%) 0 (0%)
Multiplicity
Single 2802 (93.5%) 29 (76.3%) <0.001
≥2 194 (6.5%) 9 (23.7%)
Location
Upper 1481 (50.4%) 19 (52.8%) 0.709
Mid 1003 (34.1%) 10 (27.8%)
Lower 339 (11.5%) 6 (16.7%)
Diffuse 115 (3.9%) 1 (2.8%)
Cell type
Tubular 2334 (77.9%) 32 (84.2%) 0.703
Signet ring cell 503 (16.8%) 5 (13.2%)
Mucinous 72 (2.4%) 0 (0%)
Others 87 (2.9%) 1 (2.6%)
Maximal tumor size 4.1 ± 2.8 3.0 ± 1.8 <0.001
Initial CEA 4.6 ± 21.5 3.4 ± 4.1 0.763
Initial CA 19-9 40.1 ± 319.1 8.0 ± 6.9 0.662
Smoking History
Current smoker 804 (27.2%) 14 (36.8%) 0.402
Ex-smoker 406 (13.7%) 4 (10.5%)
Never-smoker 1746 (59.1%) 20 (52.6%)
Alcoholic History
Current drinker 1235 (41.8%) 22 (57.9%) 0.048
Ex-drinker 196 (6.6%) 4 (10.5%)
Never-drinker 1521 (51.5%) 12 (31.6%)
Outcome
Alive 2290 (76.4%) 13 (34.2%)
Dead 706 (23.6%) 25 (65.8%)
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tients without MPC, while the 5-year mortality rate was
65.8% for patients with metachronous MPC.
The most common site of metachronous MPCs among
GC patients was colorectum (10 cases, 26.3%), followed
by lung (9 cases, 23.7%), liver (7 cases, 18.4%), gallblad-
der (5 cases, 13.2%), and head and neck (4 cases, 10.5%).
In addition, Of 38 patients with metachronous MPC,
34.2% were at stage I, 44.7% at stage II, and 21.1% were
at stage III.
Predictive factors for MPC
Table 2 shows a clinicopathologic comparison between
the patients with and without metachronous MPC. The
metachronous MPC group had more male (84.2% vs.
67.1%, P < 0.025) and older (63.6 ± 7.7 vs. 57.2 ± 11.8,
P < 0.001) patients than the group without MPC. In
addition, the stage of GC was earlier in patients with
metachronous MPC than in patients without MPC
(P = 0.011). No stage IV GC patients developed themetachronous MPC probably due to relatively short sur-
vival (median survival: 10.8 months). In addition, multiple
GCs at the time of gastrectomy were more common
among patients with metachronous MPC (23.7% vs. 6. 5%,
P < 0.001). There were more patients with the history of
alcoholic drinking in metachronous MPC group (68.4% vs.
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tion, cell type of GC, initial CEA level, initial CA 19–9
level, and smoking history between two groups.
Multivariate logistic regression analyses were performed
for variables that showed significance in the univariate
analysis. For metachronous MPC cases, age older than
60 years at the time of GC diagnosis, early stage (I, II) of
GC, and multiplicity of GC were independent predictive
factors (Table 3).
MPC and survival disadvantages
The 5-year survival rate for all patients was 75.9%. This
high survival rate seemed to be caused by a relatively
high proportion of earlier stage GC (stage I cancer:
53.5%, stage II: 14.6%), which is the result of the nation-
wide screening program for GC in Korea.
The 5-year survival rate was 76.5% for patients without
MPC, 67.5% for patients with metachronous MPC, and
34.1% for patients with synchronous MPC (Figure 1).
Comparison of the survival curves of the metachronous
and synchronous MPC patients to that of patients with-
out MPC showed that both metachronous MPC and
synchronous MPC patients had poorer survival than
patients without MPC (P < 0.001 and P < 0.001, respect-
ively). In addition, analysis of patients by the stage
of GC showed that the survival of patients with meta-
chronous MPC was poorer than that of patients without
MPC for all stages (P < 0.001 for stage I, P = 0.004 for
stage II, and P = 0.039 for stage III).
Patients with metachronous and synchronous MPC
showed different patterns of cause of death. Among 38
metachronous MPC patients, 25 (65.8%) died during
follow-up, in which the major cause of death was the
progression of MPC. In contrast, of 32 synchronous
MPC patients, 22 (68.8%) died during follow-up, in
which the major cause of death was the progression of
both GC and MPC.
Nomogram
For prediction of developing metachronous MPC, we
tried to generate a nomogram based on Cox regression.Table 3 Logistic regression analyses of risk factors for
metachronous MPC
Metachronous MPC
Variables RR (95% CI) P value
Sex (female vs male) 1.51 (0.54-4.21) 0.436
Age (<60 vs ≥60) 2.46 (1.20-5.07) 0.014
Stage (III, IV vs I, II) 4.82 (1.37-16.97) 0.014
Multiplicity (Single vs Multiple) 6.76 (3.05-14.96) <0.001
Maximal length (≥3.5 cm vs <3.5 cm) 1.35 (0.64-2.84) 0.428
Alcohol history (No vs Yes) 1.87 (0.83-4.22) 0.131From the Cox regression model, male (p = 0.029), age
over 60 years (p = 0.002), multiplicity of GC (p < 0.001),
and earlier stage (p = 0.026) were associated with the de-
velopment of metachronous MPC. We tried to improve
the c-index by several strategies such as combining and
adding various variables and finally generated the nomo-
gram from 5 parameters that were determined at the
time of gastrectomy (Figure 2A). The concordance index
of the model was 0.72. Figure 2B illustrates the calibra-
tion plot of the nomogram. The practical application
of this nomogram is as follows: one patient got 0 point
for his sex (male), 0 point for his age (≥60), 0 point for
multiplicity of GC (multiple gastric lesions), 0 point for
stage of GC (stage II), and 20 point for tumor size
(<3.5 cm), giving a total of 20 points. By relating the axes
of total points and the probability of MPC, we are able
to predict his probability of developing metachronous
MPC in 5-year is about 9%.
Discussion
Advances in diagnostic techniques and new chemothera-
peutic drugs have improved the clinical outcome of can-
cer, and more cancer patients are surviving longer after
their initial diagnosis [16]. In general, improved survival
is suggested to be associated with an increased risk of
developing MPC [17].
Although the major reason for the increased preva-
lence of MPC is increased survival, and therefore an
extended risk period, other possible explanations have
been proposed. First, genetic vulnerability associated
with specific genes may play a role in the development
of MPC. For example, hereditary nonpolyposis colorectal
cancer, which is a syndrome associated with mutations
in a class of genes such as MLH1, MSH2, and MSH6, is
characterized by an increased susceptibility to other ma-
lignancies, especially of the uterus, ovary, urinary tract,
and stomach [18,19]. Second, some carcinogenic en-
vironmental factors may induce multiple neoplasms of
independent organs that were exposed to same carcino-
gens. The field cancerization effect, which is associated
with an increased risk of multiple cancers in aero-
digestive organs after prolonged exposure to cigarette
smoking, is a well-known example of this phenomenon
[20]. Lastly, modalities used in the treatment of the
index cancer may also induce secondary cancers. For ex-
ample, a relationship has been reported between com-
bined therapy with radiotherapy and alkylating agents
and an increased risk of gastric and colon cancer in sur-
vivors of Hodgkin’s lymphoma [21,22].
In GC, which is the fourth most common cancer in
the world, the trend toward increasing MPC is similar.
In the present study, of the 3066 GC patients who
underwent curative gastrectomy, 70 patients (2.3%) had
been diagnosed with a metachronous or synchronous
Figure 1 MPC and survival disadvantages in GC patients. The Kaplan-Meyer survival curves according to the type of MPC. P < 0.001 for
Meta-MPC vs. No MPC, p < 0.001 for Syn-MPC vs. No MPC.
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ports that reported a range from 2.0 to 7.6% [7-9,11,23].
Few previous studies have reported the incidence and
clinical pattern of MPC in GC patients who underwent
curative gastrectomy. The majority of studies regarding
MPC in GC have been performed in Eastern countries,Figure 2 Nomogram for prediction of 5-year probability of developin
metachronous MPC. Find the value of each variables on the variable axis a
corresponding points for the variable. Sum the points achieved for each va
line down to the 5-year probability axis to determine the patient’s probabi
(B) Calibration plot for 5-year nomogram prediction. An ideal nomogram (
indicate 95% confidence intervals.with fewer studies performed in Western countries. Eom
et al. reported that, in Korea, the most common MPC is
colorectal cancer (20.8%), followed by lung cancer
(11.9%) and liver cancer (11.3%) [7]. Ikeda et al. similarly
reported that, in Japan, the most common MPC is colo-
rectal cancer (32.6%), followed by lung cancer (28.4%)g metachronous MPC. (A) Nomogram for the prediction of
nd draw a vertical line upward to the ‘Points’ axis and determine the
riables and locate this sum on the ‘Total Points’ axis. Draw a vertical
lity of developing metachronous MPC within 5 years of gastrectomy.
dashed line) and the current nomogram (solid line). Vertical bars
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reported that, in Sweden, the most common site is the
colorectum (19.9%), followed by lung (6.1%) and kidney
(5.3%) [23]. In the present study, the most common site of
metachronous MPC was the colorectum (26.3%), followed
by lung (23.7%) and liver (18.4%), which were similar to
other Asian report.
In the present study, the authors were able to identify
predictive factors for metachronous MPC. The logistic
regression analysis revealed that age over 60 years at the
time of GC diagnosis, earlier stage GC (stage I, II), and
multiplicity of GC at the time of gastrectomy were inde-
pendent predictive factors for developing metachronous
MPCs. When GC patients had multiple GC lesions at
the time of gastrectomy, the 5-year cumulative incidence
of MPC during follow-up was as high as 10.4%.
The survival analysis of this study showed that GC
survivors with MPC had a remarkably poor survival
when compared to patients without MPC. This survival
disadvantage was most prominent for patients with early
stage GC. Because the incidence of MPC was highest in
early stage GC patients, they are possible candidates for
MPC screening. In addition, patients with synchronous
MPC showed the worst survival rate, and most death
events occurred within the first 2 years following the
gastrectomy. For metachronous MPC cases, however,
the survival rate was fairly similar to that of patients
without MPC until 5 years after gastrectomy, but after
that time, the survival rate decreased rapidly. That is,
metachronous MPC showed a late survival disadvantage,
while synchronous MPC showed an early survival disad-
vantage. One possible explanation is that synchronous
cancers may have negative influences on the general
medical condition of the patient, thus hindering suitable
therapeutic strategies for treatment of GC. In contrast,
metachronous MPC develop many years after the treat-
ment of GC and it does not change the treatment of GC
in itself.
Another important point of the present study is that
we were able to develop and internally validate a predict-
ive nomogram for 5-year probability of developing
metachronous MPC in GC patients following the cura-
tive gastrectomy. The c-index of this nomogram is 0.72,
which means that its predictive accuracy is 72%. Though
this nomogram could have been biased due to insuffi-
cient MPC event, to our knowledge, this is the first
nomogram to predict metachronous MPC in GC
patients. We fully expect that this nomogram could
provide a more personalized prediction of MPC than in-
dependent risk factor models. Because the presented in-
cidence of MPCs was so small, it may have biased the
overall accuracy of the nomogram. Although the nomo-
gram is not perfectly precise, our results provide better
prediction of MPCs compared to other method. Furtherexternal validation with other independent group of pa-
tients is desirable to overcome this weakness and to im-
prove the accuracy of our nomogram.
The small incidence of MPC in GC survivors was the
major limitation of this study. In the present study, we
applied very strict criteria to diagnose MPCs, which
might be the cause of small incidence of MPCs. Because
our study is fundamentally a retrospective study, it was
hard to acquire the satisfactory patient data; we excluded
as many as 27 ambiguous cases in which the distinction
between MPCs and metastasis was not clear. In addition,
the duration of the median follow-up (60.3 months) is
not sufficient for the development of MPCs. Because of
these limitations, this study showed relatively low inci-
dence of MPCs. In reality, the incidence of MPC is not
very rare. According to the National Cancer Institute’s
SEER (Surveillance, Epidemiology, and End Results)
data, in which the data collection was between 1973 and
2003, the incidence of MPC was approximately 9% [17].
The risk varies according to the type of primary index
tumor ranging from 1% for primary liver cancer to 16%
for bladder cancer. Therefore, the screening program for
MPC may have a beneficial role. If we extend the
duration of follow-up in future study, it will better
characterize the predictive factors of MPCs. To date,
there are several reports regarding the development of
MPCs in GC survivors [7-9,23]. However, these are not
sufficient to justify the routine screening for the detec-
tion of MPC in all GC survivors; it is also difficult to ad-
dress the optimal screening protocol. Despite these
considerations, because the incidence of MPC was not
very rare and it negatively affected the clinical outcome
of GC survivors in this and previous studies, we need to
consider the possibility of MPCs, especially in the lesions
where MPCs occur frequently. In particular, because this
study showed that 63% of metachronous MPC devel-
oped within the abdominal cavity and 76% of meta-
chronous MPCs developed within 3 years after the
gastrectomy, we consider it necessary for clinicians to
pay particular attention to the follow-up abdominal im-
aging of GC survivors for at least 3 years after GC diag-
nosis. We assume that there will be, in fact, more cases
of overlooked MPCs by misdiagnosis as metastases of
GCs. Aggressive tissue biopsy can be helpful in differen-
tial diagnosis, and can play a decisive role in determining
proper treatment strategies in GC patients with predict-
ive factors such as old age at the time of diagnosis
(≥60 years), early stage (I, II), and multiplicity of GCs.
Conclusion
In conclusion, in this study, we could analyze the inci-
dence and clinical pattern of MPC following the curative
gastrectomy in GC patients. In particular, we could un-
earth that factors such as old age at the time of GC
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http://www.biomedcentral.com/1471-2407/13/394diagnosis (≥60), earlier stage GC (stage I, II), and mul-
tiple GC are valuable predictive factor for MPC. Further-
more, we have generated and validated a nomogram for
predicting individual probability of developing meta-
chronous MPC. If we could screen the development of
metachronous MPC by using these useful tools, we
could improve the clinical outcome of GC survivors.
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